Mechanism

TrialResults-center.org

Menu

histone deacetylase (HDAC) inhibitors

Entinostat

advanced breast cancer (metastatic), in all type of patients

Endpoint	TE [95% CI]	p val	I2	n	k

Trial	Studied treatment	Control	Patients
ENCORE 301, 2013	entinostat 5 mg once per week + exemestane 25 mg daily	exemestane plus placebo	Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor

Entinostat

advanced breast cancer (metastatic), in HR+ HER2-

Endpoint	TE [95% CI]	p val	I2	n	k

Trial	Studied treatment	Control	Patients
ENCORE 301, 2013	entinostat 5 mg once per week + exemestane 25 mg daily	exemestane plus placebo	Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -